<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00496080</url>
  </required_header>
  <id_info>
    <org_study_id>300-06-004</org_study_id>
    <nct_id>NCT00496080</nct_id>
  </id_info>
  <brief_title>Doppler-Guided Uterine Artery Occlusion (DUAO) Device for Fibroid Related Bleeding</brief_title>
  <acronym>DUAO</acronym>
  <official_title>A Pivotal Study of Doppler Guided Uterine Artery Occlusion as Treatment for the Reduction of Fibroid Associated Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ethicon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ethicon, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and effectiveness of Doppler guided
      uterine artery occlusion (D-UAO) for the reduction of fibroid associated bleeding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The GYNECARE GYNOCCLUDE D-UAO Instruments are single-use disposable instruments consisting of
      a GYNECARE GYNOCCLUDE Uterine Stabilizer, a GYNECARE GYNOCCLUDEM Introducer Sheath, a
      GYNECARE GYNOCCLUDE Doppler Clamp, and a GYNECARE GYNOCCLUDE Coupler.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Trial terminated early due to results from a similar study.
  </why_stopped>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>No Surgical Re-intervention</measure>
    <time_frame>Study completion</time_frame>
    <description>Number of participants without any subsequent surgical procedure intended to manage fibroid symptoms performed. Potential procedures included surgical hysterectomy or dilatation and curettage (D&amp;C) for treatment of menorrhagia; uterine artery embolization (UAE) or laparoscopic uterine artery occlusion; endometrial resection or ablation; myomectomy or myolysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in Pictorial Blood Loss Assessment Chart (PBLAC) Score</measure>
    <time_frame>From baseline to 12 months</time_frame>
    <description>Number of participants with a 50% or greater reduction in PBLAC score from baseline at 12 mo and a PBLAC score of less than 250. PBLAC is a simple validated semiquantitative method of measuring total menstrual blood loss using a pictorial representation of blood loss, where higher scores indicate more blood loss. This hybrid endpoint combined the reduction in PBLAC score with the total PBLAC score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Improvement in Health Related Quality of Life (HRQOL) Scores</measure>
    <time_frame>From baseline to 12 months</time_frame>
    <description>Participants categorized as &quot;better&quot; in the total UFS-QOL questionnaire, indicating an overall improvement in health-related quality of life. On this scale, higher scores are indicative of better quality of life, with a maximum(best)score of 100 and a minimum (worst)score of 0. &quot;Better&quot; was defined as a change of +12 or more from baseline at 12 mo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance of Menses</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with continuation of menstrual cycles without interruption for three consecutive months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Satisfaction</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with responses of either &quot;satisfied&quot; or &quot;very satisfied&quot; on a qualitative survey that ranged from &quot;very dissatisfied&quot; (worst) to &quot;very satisfied&quot; (best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in Fibroid Bulk</measure>
    <time_frame>From baseline to 12-months</time_frame>
    <description>Number of participants with a minimum 15% decrease in fibroid bulk based on independent magnetic resonance imaging (MRI) review from baseline at 12 mo.
Note: As per protocol, MRIs were planned only for subjects 1 - 40, 81 - 120, and 161-200.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Improvement in Uterine Fibroid Symptom Quality of Life (UFS-QOL) Symptom Severity Scores</measure>
    <time_frame>From baseline to 12 months</time_frame>
    <description>Number of participants categorized as &quot;better&quot; in the UFS-QOL sympton severity questionnaire, indicating an overall improvement in fibroid related symptoms. On this scale, higher scores are indicative of increasing symptom distress, with a maximum(worst)score of 100 and a minimum (best)score of 0. &quot;Better&quot; was defined as a change of -11 or less from baseline at 12 mo.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Menorrhagia</condition>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>DUAO Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doppler-guided uterine artery occlusion device (Single-arm study)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Doppler-Guided Uterine Artery Occlusion Device (DUAO)</intervention_name>
    <description>Investigational transvaginal clamp inserted one time for 6 hours.</description>
    <arm_group_label>DUAO Device</arm_group_label>
    <other_name>floSTAT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  25 to 50 years of age;

          -  PBLAC score of 150 or greater;

          -  Completed child-bearing;

          -  Normal Pap smear within 12 months;

          -  Cervix suitable for tenaculum placement as determined by pelvic exam;

          -  At least one uterine fibroid of 3 cm diameter or greater with a prevailing pathology
             (e.g., as opposed to adenomyosis) of fibroids determined through ultrasound;

          -  Willing to maintain use or non-use of hormonal contraception from 3 months pre-study
             throughout the 12-month follow-up period;

          -  Willing to maintain use or non-use of anti-fibrinolytic agents from 3 months pre-study
             throughout the 12-month follow-up period;

          -  Able to tolerate the required prolonged supine position during treatment
             (approximately 6 hours);

          -  Willing and able to provide informed consent and to follow study-related requirements;

        Exclusion Criteria:

          -  Pregnancy (as confirmed immediately prior to procedure)

          -  Fibroid diameter greater than 8.0 cm determined through transvaginal ultrasound; [or
             if 2 dimensions are measured, total dimension greater than 16 cm; or if the 3
             dimensions (length, height, width) are measured, total dimension greater than 24 cm];

          -  Presence of a pedunculated fibroid determined by ultrasound; hysteroscopy, or saline
             infused sonography;

          -  Hydronephrosis as determined by radiologist interpretation on renal ultrasound
             pre-procedurally;

          -  Menopausal;

          -  Clinical history of any thromboembolic disease;

          -  Blood urine nitrogen (BUN) greater than 20 mg/dL and/or serum creatinine greater than
             1.2 mg/dL unresolved with change in diet or hydration; Â· One or more lower uterine
             segment fibroids determined through pelvic exam;

          -  History of gynecologic malignancy, atypical endometrial hyperplasia, or pelvic
             inflammatory disease;

          -  Abnormal endometrial biopsy within the last 6 months prior to procedure;

          -  Pelvic mass outside the uterus suggesting other disease processes;

          -  Any current acute or chronic systemic infection or localized pelvic infection,
             including an unresolved urinary tract infection;

          -  Using GnRH agonist or mifepristone within 6-months prior to the start of the study;

          -  An intrauterine device (IUD) in place;

          -  Using anticoagulation therapy (except OTC treatments (e.g. aspirin)), or have an
             underlying bleeding disorder;

          -  Unsuitable for MRI examination, if within study subgroup to undergo MRI evaluation
             (e.g. severe claustrophobia, non-MRI-compatible implanted metalloid devices);

          -  Prior endometrial ablation, uterine artery embolization, or uterine artery ligation;

          -  Poor procedural candidate due to medical conditions as determined by the investigator
             (e.g. anesthesia class, renal insufficiency, heart disease);

          -  Grade 1 for 3D Color Doppler or no flow observed for cystoscopy on ureter flow
             assessment if applicable.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piet Hinoul, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Ethicon, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Women's Health Research</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015-2110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Cross Medical Group</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Women's Care - Wayne State University</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Gynecology and Surgery</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Children's &amp; Adults' Clinical Research Foundation</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complete Healthcare for Women</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hahnemann University Hospital - Drexel University School of Med.</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matlock Ob/Gyn</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Health Care</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2007</study_first_submitted>
  <study_first_submitted_qc>July 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2007</study_first_posted>
  <results_first_submitted>June 19, 2012</results_first_submitted>
  <results_first_submitted_qc>June 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 24, 2012</results_first_posted>
  <last_update_submitted>September 6, 2012</last_update_submitted>
  <last_update_submitted_qc>September 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Menorrhagia associated with Uterine Fibroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
    <mesh_term>Menorrhagia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment took place from June 2007 through May 2009. Sites included hospitals, surgical centers and private practices in North America.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>DUAO Device</title>
          <description>Doppler-guided uterine artery occlusion device (Single-arm study)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Surgical re-intervention</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DUAO Device</title>
          <description>Doppler-guided uterine artery occlusion device (Single-arm study)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="87"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.3" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>No Surgical Re-intervention</title>
        <description>Number of participants without any subsequent surgical procedure intended to manage fibroid symptoms performed. Potential procedures included surgical hysterectomy or dilatation and curettage (D&amp;C) for treatment of menorrhagia; uterine artery embolization (UAE) or laparoscopic uterine artery occlusion; endometrial resection or ablation; myomectomy or myolysis.</description>
        <time_frame>Study completion</time_frame>
        <population>ITT (Data missing for 5 participants)</population>
        <group_list>
          <group group_id="O1">
            <title>DUAO Device</title>
            <description>Doppler-guided uterine artery occlusion device</description>
          </group>
        </group_list>
        <measure>
          <title>No Surgical Re-intervention</title>
          <description>Number of participants without any subsequent surgical procedure intended to manage fibroid symptoms performed. Potential procedures included surgical hysterectomy or dilatation and curettage (D&amp;C) for treatment of menorrhagia; uterine artery embolization (UAE) or laparoscopic uterine artery occlusion; endometrial resection or ablation; myomectomy or myolysis.</description>
          <population>ITT (Data missing for 5 participants)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="82.7" upper_limit="95.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Improvement in Pictorial Blood Loss Assessment Chart (PBLAC) Score</title>
        <description>Number of participants with a 50% or greater reduction in PBLAC score from baseline at 12 mo and a PBLAC score of less than 250. PBLAC is a simple validated semiquantitative method of measuring total menstrual blood loss using a pictorial representation of blood loss, where higher scores indicate more blood loss. This hybrid endpoint combined the reduction in PBLAC score with the total PBLAC score.</description>
        <time_frame>From baseline to 12 months</time_frame>
        <population>ITT (No data for 18 participants)</population>
        <group_list>
          <group group_id="O1">
            <title>DUAO Device</title>
            <description>Doppler-guided uterine artery occlusion device</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Pictorial Blood Loss Assessment Chart (PBLAC) Score</title>
          <description>Number of participants with a 50% or greater reduction in PBLAC score from baseline at 12 mo and a PBLAC score of less than 250. PBLAC is a simple validated semiquantitative method of measuring total menstrual blood loss using a pictorial representation of blood loss, where higher scores indicate more blood loss. This hybrid endpoint combined the reduction in PBLAC score with the total PBLAC score.</description>
          <population>ITT (No data for 18 participants)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="12.7" upper_limit="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Improvement in Health Related Quality of Life (HRQOL) Scores</title>
        <description>Participants categorized as &quot;better&quot; in the total UFS-QOL questionnaire, indicating an overall improvement in health-related quality of life. On this scale, higher scores are indicative of better quality of life, with a maximum(best)score of 100 and a minimum (worst)score of 0. &quot;Better&quot; was defined as a change of +12 or more from baseline at 12 mo.</description>
        <time_frame>From baseline to 12 months</time_frame>
        <population>ITT (No data for 20 participants)</population>
        <group_list>
          <group group_id="O1">
            <title>DUAO Device</title>
            <description>Doppler-guided uterine artery occlusion device</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Improvement in Health Related Quality of Life (HRQOL) Scores</title>
          <description>Participants categorized as &quot;better&quot; in the total UFS-QOL questionnaire, indicating an overall improvement in health-related quality of life. On this scale, higher scores are indicative of better quality of life, with a maximum(best)score of 100 and a minimum (worst)score of 0. &quot;Better&quot; was defined as a change of +12 or more from baseline at 12 mo.</description>
          <population>ITT (No data for 20 participants)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance of Menses</title>
        <description>Number of participants with continuation of menstrual cycles without interruption for three consecutive months</description>
        <time_frame>12 months</time_frame>
        <population>ITT (No data for 30 participants)</population>
        <group_list>
          <group group_id="O1">
            <title>DUAO Device</title>
            <description>Doppler-guided uterine artery occlusion device</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance of Menses</title>
          <description>Number of participants with continuation of menstrual cycles without interruption for three consecutive months</description>
          <population>ITT (No data for 30 participants)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Satisfaction</title>
        <description>Number of participants with responses of either &quot;satisfied&quot; or &quot;very satisfied&quot; on a qualitative survey that ranged from &quot;very dissatisfied&quot; (worst) to &quot;very satisfied&quot; (best)</description>
        <time_frame>12 months</time_frame>
        <population>ITT (No data for 19 participants)</population>
        <group_list>
          <group group_id="O1">
            <title>DUAO Device</title>
            <description>Doppler-guided uterine artery occlusion device (Single-arm study)</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Satisfaction</title>
          <description>Number of participants with responses of either &quot;satisfied&quot; or &quot;very satisfied&quot; on a qualitative survey that ranged from &quot;very dissatisfied&quot; (worst) to &quot;very satisfied&quot; (best)</description>
          <population>ITT (No data for 19 participants)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Undecided</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Decrease in Fibroid Bulk</title>
        <description>Number of participants with a minimum 15% decrease in fibroid bulk based on independent magnetic resonance imaging (MRI) review from baseline at 12 mo.
Note: As per protocol, MRIs were planned only for subjects 1 - 40, 81 - 120, and 161-200.</description>
        <time_frame>From baseline to 12-months</time_frame>
        <population>ITT (Due to early termination, only 39 subjects had MRIs. No data for 8 participants.)</population>
        <group_list>
          <group group_id="O1">
            <title>DUAO Device</title>
            <description>Doppler-guided uterine artery occlusion device (Single-arm study)</description>
          </group>
        </group_list>
        <measure>
          <title>Decrease in Fibroid Bulk</title>
          <description>Number of participants with a minimum 15% decrease in fibroid bulk based on independent magnetic resonance imaging (MRI) review from baseline at 12 mo.
Note: As per protocol, MRIs were planned only for subjects 1 - 40, 81 - 120, and 161-200.</description>
          <population>ITT (Due to early termination, only 39 subjects had MRIs. No data for 8 participants.)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Improvement in Uterine Fibroid Symptom Quality of Life (UFS-QOL) Symptom Severity Scores</title>
        <description>Number of participants categorized as &quot;better&quot; in the UFS-QOL sympton severity questionnaire, indicating an overall improvement in fibroid related symptoms. On this scale, higher scores are indicative of increasing symptom distress, with a maximum(worst)score of 100 and a minimum (best)score of 0. &quot;Better&quot; was defined as a change of -11 or less from baseline at 12 mo.</description>
        <time_frame>From baseline to 12 months</time_frame>
        <population>ITT (No data for 18 participants.)</population>
        <group_list>
          <group group_id="O1">
            <title>DUAO Device</title>
            <description>Doppler-guided uterine artery occlusion device (Single-arm study)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Improvement in Uterine Fibroid Symptom Quality of Life (UFS-QOL) Symptom Severity Scores</title>
          <description>Number of participants categorized as &quot;better&quot; in the UFS-QOL sympton severity questionnaire, indicating an overall improvement in fibroid related symptoms. On this scale, higher scores are indicative of increasing symptom distress, with a maximum(worst)score of 100 and a minimum (best)score of 0. &quot;Better&quot; was defined as a change of -11 or less from baseline at 12 mo.</description>
          <population>ITT (No data for 18 participants.)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <desc>Due to early study termination the longest timeframe of a patientâs study participation was 2 years and 9 days. The shortest timeframe of study participation was 11 months 9 days.</desc>
      <group_list>
        <group group_id="E1">
          <title>DUAO Device</title>
          <description>Doppler-guided uterine artery occlusion device (Single-arm study)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Medication Error</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Vaginal Discharge</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated early because 6 mo interim analysis of parallel European study showed that device was not meeting the primary endpoint. Target enrollment was 200 subjects, but results are based on 87 subjects who were treated with the device.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Piet Hinoul MD</name_or_title>
      <organization>Ethicon</organization>
      <phone>908-218-2585</phone>
      <email>phinoul@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

